Cargando…
Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour?
Itolizumab is a first-in-class anti-CD6 monoclonal antibody that was initially developed for various cancers and was later developed and approved in India for treatment of moderate to severe chronic plaque psoriasis in 2013. This drug is now being re-purposed for COVID-19. The potential utility of i...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551520/ https://www.ncbi.nlm.nih.gov/pubmed/33048300 http://dx.doi.org/10.1007/s40259-020-00448-5 |